Evidence map›Paper›PMID 38280393›Full record

Observational studyThe lancet. HIV2024

Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies.

Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hessamfar, Peter Reiss, Katharina Kusejko, Michael J Silverberg and 11 more

Abstract readObservational Study
In one paragraph

Observational study in The lancet. HIV, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Older people living with HIV: a population with high prevalence and severity of metabolic dysfunction-associated steatotic liver disease ‒ A cross-sectional study.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026
    Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Adam TrickeyPopulation Health Sciences, University of Bristol, Bristol, UK. Electronic address: adam.trickey@bristol.ac.uk.
Kathleen McGinnisVA Connecticut Healthcare System, West Haven, CT, USA.
M John GillDepartment of Medicine, University of Calgary, South Alberta HIV Clinic, Calgary, AB, Canada.
Sophie AbgrallAssistance Publique-Hôpitaux de Paris (APHP), Hôpital Béclère, Service de Médecine Interne, Clamart, France; APHP, Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP INSERM U1018, Le Kremlin-Bicêtre, France.
Juan BerenguerHospital General Universitario Gregorio Marañón, IiSGM, CIBERINFEC, Madrid, Spain.
Christoph WyenDepartment I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Mojgan HessamfarUniversity of Bordeaux, ISPED, INSERM U1219, Bordeaux, France; Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.
Peter ReissStichting HIV Monitoring, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Global Health, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
Katharina KusejkoDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Arkaitz ImazDepartment of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
Ramon TeiraServicio de Medicina Interna, Hospital Universitario de Sierrallana, Torrelavega, Spain.
Antonella d'Arminio MonforteUniversity of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy.
Robert ZangerleDepartment of Dermatology, Venereology and Allergy, Medical University Innsbruck, Innsbruck, Austria.
Jodie L GuestAtlanta VA Medical Center, Decatur, GA, USA; Rollins School of Public Health at Emory University, Atlanta, GA, USA.
Vasileios Papastamopoulos5th Department of Internal Medicine & Infectious Diseases Unit, Evangelismos General Hospital, Athens, Greece.
Heidi CraneDivision of Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Timothy R SterlingDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Sophie GrabarSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France; Department of Public Health, AP-HP, St Antoine hospital, Paris, France.
Suzanne M InglePopulation Health Sciences, University of Bristol, Bristol, UK.
Jonathan A C SternePopulation Health Sciences, University of Bristol, Bristol, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; Health Data Research UK South-West, Bristol, UK.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2015 to 2026
$27.5M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
2/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026230 · NIAAA · KAISER FOUNDATION RESEARCH INSTITUTE · PI SATRE, DEREK D, SILVERBERG, MICHAEL J · 2017 to 2021
$3.0M
3/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026224 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2017 to 2021
$2.9M
1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VAU01AA026209 · NIAAA · UNIVERSITY OF BRISTOL · PI STERNE, JONATHAN · 2017 to 2021
$2.2M
NIAAA NIH HHS U01 AA026209NIAAA NIH HHS U01 AA026224NIAAA NIH HHS U01 AA026230NIAAA NIH HHS U24 AA020794NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI110527NIAID NIH HHS R24 AI067039Wellcome Trust
6 · The paper itself

Abstract

backgroundMortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.

methodsIn this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.

findingsAmong 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).

interpretationReductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.

fundingUS National Institute on Alcohol Abuse and Alcoholism.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsNeoplasmsAdolescentAdultCause of DeathCohort StudiesEuropeFemaleHumansMaleNorth AmericaRisk Factors

Identifiers

PMID38280393
PMCPMC11656032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.